ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.53
1.40%
US Tech 100
17,598.80
1.03%
S&P 500
5,180.74
1.03%
US Dollar vs CAD
1.36775
0.05%
Bitcoin
63,386.33
0.35%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Iterum Therapeutics PLC (ITRM)

  7. Iterum Therapeutics PLC (ITRM) News

ITRM

Iterum Therapeutics (ITRM)

Iterum Therapeutics PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ITRM
DateTimeSourceHeadlineSymbolCompany
05/06/20247:00AMGlobeNewswire Inc.Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024NASDAQ:ITRMIterum Therapeutics PLC
04/29/20247:00AMGlobeNewswire Inc.Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral SulopenemNASDAQ:ITRMIterum Therapeutics PLC
03/28/20246:42AMIH Market NewsUS Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices RiseNASDAQ:ITRMIterum Therapeutics PLC
03/28/20246:00AMGlobeNewswire Inc.Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
03/21/20243:30PMGlobeNewswire Inc.Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024NASDAQ:ITRMIterum Therapeutics PLC
03/15/20247:00AMGlobeNewswire Inc.Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside ChatNASDAQ:ITRMIterum Therapeutics PLC
03/06/20247:16AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
03/06/20247:00AMGlobeNewswire Inc.Iterum Therapeutics Provides Business UpdateNASDAQ:ITRMIterum Therapeutics PLC
01/30/20244:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
01/30/20246:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
01/30/20246:00AMPR Newswire (US)Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
12/29/20233:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
12/14/20236:45AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
12/14/20236:30AMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ITRMIterum Therapeutics PLC
12/04/20234:15PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ITRMIterum Therapeutics PLC
12/04/20234:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITRMIterum Therapeutics PLC
12/04/20237:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
12/04/20237:00AMGlobeNewswire Inc.Iterum Therapeutics Regains Compliance with Nasdaq Bid Price RuleNASDAQ:ITRMIterum Therapeutics PLC
11/07/20237:30AMGlobeNewswire Inc.Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023NASDAQ:ITRMIterum Therapeutics PLC
10/24/20238:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
10/24/20237:00AMGlobeNewswire Inc.Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
10/12/20238:15AMGlobeNewswire Inc.Iterum Therapeutics to Present Data at IDWeek 2023NASDAQ:ITRMIterum Therapeutics PLC
08/11/20236:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
08/11/20236:00AMGlobeNewswire Inc.Iterum Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
08/04/20234:00PMGlobeNewswire Inc.Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023NASDAQ:ITRMIterum Therapeutics PLC
08/01/20233:16PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
07/13/20236:07AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
07/06/20238:25AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
07/06/20238:24AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
06/15/20234:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ITRMIterum Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:ITRM

Your Recent History

USOTC
INKW
Greene Concepts (PK)
USOTC
CYDY
CytoDyn (QB)
USOTC
MVNT
Movement Industries (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
SFLM
SFLMaven (PK)
USOTC
TSOI
Therapeutic Solutions (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
NASDAQ
MULN
Mullen Automotive
USOTC
INND
Innerscope Hearing Techn... (PK)
USOTC
AFFU
Affluence (PK)
USOTC
IQST
iQSTEL (QX)
USOTC
ALYI
Alternet Systems (PK)
USOTC
AHRO
Authentic (CE)
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
ILST
International Star (PK)
USOTC
ENZC
Enzolytics (PK)
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved